Free Submission Public Relations & NewsPR-inside.com
Home
Deutsch English

Health

Now Available: Ganaxolone (Epilepsy) - Forecast and Market Analysis to 2022


Print article Print article
2013-03-18 03:16:15 - Recently published research from GlobalData, "Ganaxolone (Epilepsy) - Forecast and Market Analysis to 2022", is now available at Fast Market Research

GlobalData has released its new PharmaPoint Drug Evaluation report, "Ganaxolone (Epilepsy) - Forecast and Market Analysis to 2022". Epilepsy is a brain disorder characterized by spontaneously occurring and recurrent seizures. The market is heavily driven by the sales of antiepileptic drugs (AEDs) targeted at seizure reduction. The AED market is currently dominated by UCB's Keppra and GlaxoSmithKline's Lamictal. Although both drugs have experienced significant generic erosion, they form the mainstay of epilepsy treatment in the nine markets and will continue to have significant market share during the forecast period. Other key drugs include older generation AEDs such as Pfizer's Dilantin, Abbott's Depakote, and Novartis' Tegretol and Trileptal which still have significant usage due to their longevity in the market. However,

the AED dominance landscape will continue to shift towards newer generation drugs particularly following the recent market entry of GlaxoSmithKline's Trobalt/Potiga and Eisai's Fycompa which both offer first-in-class mechanisms of action.


Full Report Details at
- www.fastmr.com/prod/553320_ganaxolone_epilepsy_forecast_and_mark ..


Ganaxolone is a first-in-class synthetic neurosteroid analog of the endogenous neurosteroid allopregnanolone. It has novel GABA-A receptor modulation and unique broad-spectrum protective efficacy, and is under development for the treatment of uncontrolled partial-onset seizures and infantile spasms. Marinus Pharmaceuticals licensed ganaxolone from Purdue Pharma and is currently conducting late-stage Phase II trials for ganaxolone as an adjunctive therapy in adult patients with refractory partial seizures and in children with infantile spasms. Ganaxolone has been administered to more than 900 healthy adult volunteers and patients in Phase I and Phase II studies, and was shown to be well tolerated and safe in adults, children, and infants (Marinus Pharmaceuticals, 2012).

Scope

* Overview of Epilepsy, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
* Detailed information on Ganaxolone including product description, safety and efficacy profiles as well as a SWOT analysis.
* Sales forecast for Ganaxolone for the top six countries from 2012 to 2022.
* Sales information covered for the US, France, Germany, Italy, Spain and the UK

Reasons to buy

* Understand and capitalize by identifying products that are most likely to ensure a robust return
* Stay ahead of the competition by understanding the changing competitive landscape for Epilepsy
* Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
* Make more informed business decisions from insightful and in-depth analysis of Ganaxolone performance
* Obtain sales forecast for Ganaxolone from 2012-2022 in top six countries (the US, France, Germany, Italy, Spain and the UK)

Partial Table of Contents:

1 Table of Contents
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Catalyst
2.2 Related Reports
3 Disease Overview
3.1 Classification of Seizures
3.2 Etiology and Pathophysiology
3.2.1 Etiology
3.2.2 Pathophysiology
3.2.3 Prognosis
3.2.4 Quality of Life
4 Disease Management
4.1 Diagnosis
4.2 Treatment Guidelines
4.3 Clinical Practice
5 Competitive Assessment
5.1 Overview
5.2 Strategic Competitor Assessment
6 Opportunity and Unmet Need
6.1 Overview
6.2 Unmet Needs
6.2.1 Refractory Epilepsy
6.2.2 Safety/Side Effect Profiles
6.2.3 Curative/Disease-Modifying Agents
6.2.4 Predictive Tools and Need for More Directed Treatments
6.2.5 Improved Preclinical Models and Clinical Trial Paradigms
6.2.6 Treatment Gap
6.3 Unmet Needs Gap Analysis
6.4 Opportunities
6.4.1 Disease-Modifying Agents
6.4.2 Improved Preclinical Models and Clinical Trial Paradigms
6.4.3 Treatment Gap
7 Pipeline Assessment
7.1 Overview
7.2 Strategic Pipeline Assessment
7.3 Pipeline by Phases of Development
7.3.1 Phase III Pipeline
7.3.2 Phase III Pipeline - Reformulations/New Delivery Systems
7.3.3 Phase IIb Pipeline
7.3.4 Phase II Pipeline
7.3.5 Phase I Pipeline
7.3.6 Preclinical Pipeline
7.3.7 Discovery Pipeline
7.4 Pipeline by Mechanism of Action
7.5 Promising Drugs in Clinical Development
8 Ganaxolone
8.1 Overview
8.2 Efficacy
8.3 Safety
8.4 Dosing and Formulation
8.5 Potential Clinical Positioning
8.6 Potential Commercial Positioning
8.7 Pricing and Reimbursement
8.8 SWOT Analysis
8.9 Forecast
9 Appendix
9.1 Bibliography
9.2 Abbreviations
9.3 Methodology
9.4 Forecasting Methodology
9.4.1 Prevalent Epilepsy Patients
9.4.2 Percent Drug-Treated Patients
9.4.3 General Pricing Assumptions
9.4.4 Generic Erosion
9.4.5 Pricing of Pipeline Agents
9.5 Physicians and Specialists Included in this Study
9.6 Primary Research - Prescriber Survey
9.7 About the Authors
9.7.1 Authors
9.7.2 Global Head of Healthcare
9.8 About GlobalData
9.9 Contact Us
9.10 Disclaimer

List of Tables

1.1 List of Tables
Table 1: Epilepsy Syndromes by Age at Onset (2009 ILAE Classification)

Full Table of Contents is available at:
-- www.fastmr.com/catalog/product.aspx?productid=553320&dt=t

About GlobalData

GlobalData is a leading provider of global business intelligence including market, competitor, product and customer information. It provides in-depth research, analysis, data and forecasts through a range of interactive online databases, reports and management briefings. GlobalData has a large team of experienced research and analysis, consulting, and marketing experts. It has a global presence, including key offices in the US, Europe and Asia. The group has over 50 years of experience of delivering market intelligence data and analysis and a highly experienced senior management team. View more research from GlobalData at www.fastmr.com/catalog/publishers.aspx?pubid=1015

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at www.fastmr.com or call us at 1.800.844.8156.


Author:
Bill Thompson
e-mail
Web: www.fastmr.com
Phone: 18008448156

Disclaimer: If you have any questions regarding information in these press releases please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims contents contained in this release.
Latest News
Read the Latest News
www.newsenvoy.com

 


Terms & Conditions | Privacy | About us | Contact PR-inside.com